2 May 2018 07:41
Omega Diagnostics Group PLC
("Omega" or "the Company" or the "Group")
Closure of Omega Diagnostics GmbH
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the closure of Omega Diagnostics GmbH ("Omega GmbH").
Further to the announcement on 10 April 2018, the Board has not been able to conclude any transaction for a sale of Omega GmbH. The Board has therefore decided to initiate insolvency proceedings through the German court system, as soon as practically possible, under the guidance of its legal advisers. The contingent cost associated with this closure is not expected to be more than £0.45m and could be significantly less than this figure.
For the year ended 31 March 2018, Omega GmbH had sales of approximately €3.2 million* and incurred an EBITDA loss of approximately €0.4 million*.
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
* Figures for the year ended 31 March 2018 are unaudited as at the date of this release.
Contacts:
Omega Diagnostics Group PLC | Tel: 01259 763 030 |
Colin King, Chief Executive | www.omegadiagnostics.com |
Kieron Harbinson, Group Finance Director |
|
|
|
finnCap Ltd | Tel: 020 7220 0500 |
Geoff Nash/James Thompson (Corporate Finance) |
|
Camille Gochez/ Abigail Wayne (Corporate Broking) |
|
|
|
Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |